Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 known ✓ | P18405 | 19/20 | 1.00 |
| ▸ | SRD5A2 known ✓ | P31213 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutasteride SCHEMBL1832772 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1285958 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL9975973 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL5903 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1108295 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL13495828 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL10028296 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL12194984 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL20776136 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL4775587 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563728-B2 | Process for the preparation of Dutasteride | AUROBINDO PHARMA LTD. (IN) | 2013-10-22 | — | — | US | claimed |
| US-20120157683-A1 | PROCESS FOR THE PREPARATION OF DUTASTERIDE | AUROBINDO PHARMA LTD (IN) | 2012-06-21 | — | — | US | claimed |
| US-7998970-B2 | Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders | PROTEOSYS AG (DE) | 2011-08-16 | — | — | US | claimed |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2009-07-02 | — | — | US | claimed |
| EP-1824495-A2 | FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS | ProteoSys AG (DE) | 2007-08-29 | — | — | EP | claimed |
| WO-2006058781-A2 | FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2006-06-08 | — | — | WO | claimed |
| US-7022854-B2 | Forms of dutasteride and methods for preparation thereof | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2006-04-04 | — | — | US | claimed |
| US-20050059692-A1 | Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one | DR. REDDY'S LABORATORIES LIMITED | 2005-03-17 | — | — | US | claimed |
| US-20040077673-A1 | Forms of dutasteride and methods for preparation thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-04-22 | — | — | US | claimed |
| EP-0859617-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997011702-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-04-03 | — | — | WO | claimed |
| US-11857556-B2 | Topical compositions of dutasteride | SHILPA MEDICARE LIMITED (IN) | 2024-01-02 | — | — | US | disclosed |
| US-11771690-B2 | Solid particle, preparation method therefor, and pharmaceutical composition containing solid particle | SHANGHAI WD PHARMACEUTICAL CO., LTD (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11311529-B2 | Topical formulations of 5-α-reductase inhibitors and uses thereof | VARSONA THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10993934-B2 | Topical compositions of dutasteride | SHILPA MEDICARE LIMITED (IN) | 2021-05-04 | — | — | US | disclosed |
| US-5846976-A | Androstenone derivative | GLAXO WELLCOME INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0719278-B1 | ANDROSTENONE DERIVATIVE | GLAXO WELLCOME INC (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5565467-A | 17-BETA-N-(2,5-BIS(TRIFLUOROMETHYL)PHENYLCARBAMOYL-4-AZA-5-AL PHA-ANDROST-1-EN-3-ONE; USED IN THE TREATMENT OF ANDROGEN RESPONSIVE AND MEDIATED DISEASES | GLAXO WELLCOME INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0719278-A1 | ANDROSTENONE DERIVATIVE | GLAXO WELLCOME INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007927-A1 | ANDROSTENONE DERIVATIVE | GLAXO WELLCOME INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077673-A1 | Forms of dutasteride and methods for preparation thereof | SRD5A2, NR5A1, CYP17A1 | SRD5A1 8/4885SRD5A2 1/4885LMNA 3001/4885 |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | SLC25A4, CHRNA10, SLC25A20 | SRD5A1 511/4885SRD5A2 708/4885LMNA 2435/4885 |
| US-11857556-B2 | Topical compositions of dutasteride | AR, CYP21A2, CYP17A1 | SRD5A1 10/4885SRD5A2 8/4885LMNA 4032/4885 |
| US-11771690-B2 | Solid particle, preparation method therefor, and pharmaceutical composition containing solid particle | MGLL, FAR1, NOTUM | SRD5A1 1092/4885SRD5A2 1346/4885LMNA 2624/4885 |
| US-20120157683-A1 | PROCESS FOR THE PREPARATION OF DUTASTERIDE | CYP21A2, CYP17A1, HSD17B7 | SRD5A1 15/4885SRD5A2 4/4885LMNA 2719/4885 |
| US-10993934-B2 | Topical compositions of dutasteride | AR, CYP21A2, CYP17A1 | SRD5A1 10/4885SRD5A2 8/4885LMNA 4032/4885 |
| US-20050059692-A1 | Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one | NR5A1, CYP17A1, CYP19A1 | SRD5A1 7/4885SRD5A2 8/4885LMNA 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.